ClinicalTrials.gg
RecruitingNCT06879977ABC-DUpdated Apr 8, 2025

Body Awareness in People With Depressive Disorder

An observational study in Depressive Disorder, sponsored by Johannes Kepler University of Linz. Recruiting at 1 site in Austria. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Johannes Kepler University of Linz · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
125
Ages
18 Years to 69 Years
Sex
All
01

Study summary

Body awareness plays a crucial role in health and well-being. However, too little research has been carried out on how it manifests in individuals with depressive disorders. The Awareness Body Chart (ABC), a tool developed in recent years to assess body awareness, may provide new insights into the physical experience of people with depression and may lead the way in the application of body-oriented therapies in this cohort. Information about the distribution properties of the Awareness Body Chart in people with depressive disorder will be collected and analysed in this observational study.

Read the detailed description

Research Questions:

  • Primary Research Question What are the distribution properties of the body awareness assessed by the ABC?
  • Secondary Research Questions (exploratory)

    1. Which factors (demographic, physical, psychological) correlate with body awareness?
    2. Does body awareness and mood change during an inpatient stay? Method: Observational Study Participants: 125 patients with depressive disorders at the beginning and end of an inpatient stay.

Assessments via Questionnaires:

Completion of questionnaires (partially with assistance) within the first 7 days after admission:

  • Demographic data and questions about health/relevant pre-existing conditions, including body weight and height, i.e. Body Mass Index
  • Awareness Body Chart (ABC)
  • Like/Dislike Body Chart (L/D-BC)
  • Self-Rating Mood Scale-Revised (Bf-SR)
  • Simple Physical Activity Questionnaire (SIMPAQ)
  • Short Form Health Survey (SF-12)
  • Brief Symptom Inventory (BSI)
  • Beck Depression Inventory II (BDI-II)
  • Insomnia Severity Index (ISI)

Pre-Discharge Questionnaire Completion:

  • ABC
  • L/D-BC
  • Bf-SR
  • BDI-II
  • ISI

Statistical Analysis:

For the analysis of the primary outcome, the ABC score for the entire sample will be presented using the mean and standard deviation or median and interquartile range, depending on the distribution properties of the ABC score. For the analysis of secondary questions, the total scores of the ABC and factor scores will be compared between men and women, between patients with and without pain, using t-tests or Mann-Whitney U-tests, and between individuals with different categories of depressive disorders or varying severities of depression using ANOVA or Kruskal-Wallis tests.

Furthermore, the correlation of body awareness with demographic data, body mass index, diagnosis group, disease duration, test results from SIMPAQ, SF-12, BSI, Bf-SR, and ISI will be investigated using correlation analyses, where the correlation coefficient will be calculated either using Pearson or Spearman, depending on the distribution of the data. Changes in body awareness and well-being during an inpatient stay will be analyzed using paired t-tests or Wilcoxon signed-rank tests.

Outlook:

The study serves as a basis for further research on body awareness in individuals with depressive disorders.

02

Conditions studied

  • Depressive Disorder

Keywords

  • Depression
  • Body awareness
03

In context

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

This study's planned enrollment of 125 is below the median of 174 across 140 observational studies indexed under Depressive Disorder.

Browse Depressive Disorder studies →

Lead sponsor

Johannes Kepler University of Linz is the lead sponsor of 33 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with depressive disorders at the beginning and end of an inpatient stay.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 - 69 years
  • Medical diagnosis of a depressive disorder, including depressive adjustment disorder and depressive episodes in the context of bipolar disorder, i.e. one of the following ICD-10 codes:
  • F32 Depressive Episode
  • F33 Recurrent Depressive Disorder
  • F31.3 Bipolar Affective Disorder, current mild or moderate depressive episode
  • F31.4 Bipolar Affective Disorder, current severe depressive episode without psychotic symptoms
  • F43.20 Adjustment Disorder with Brief Depressive Reaction
  • F43.21 Adjustment Disorder with Prolonged Depressive Reaction
  • Inpatient admission
  • Written

Exclusion criteria

Exclusion Criteria:

  • Inability to fill out questionnaires with or without assistance due to language, physical, or cognitive limitations
  • Acute psychotic state
  • Known body schema disorders, e.g. due to significant neurological or malignant diseases, eating disorders, congenital or acquired physical limitations such as the absence of a body part
  • Deafness, blindness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
125 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with depressive disorders

    Patients with depressive disorders at the beginning and end of an inpatient stay

06

What researchers measure

Primary outcomes

  1. Awareness Body Chart Questionnaire (ABC)

    Body charts to fill in with colours according to intensity of body awareness. In sum, 51 body regions to colour with 5 different colour pencils (orange = "I can perceive with much detail", yellow = "I can perceive distinctly", green = "I can perceive", blue = "I can perceive indistinctly", black = "I cannot perceive"). To quantify the information, every region of the body will be coded as an extra item and the data of the colours will be transcribed: orange (= 5), yellow (= 4), green (= 3), blue (= 2), black (= 1). Higher values mean higher intensity of body awareness. In the case of pain, the pain location can also be marked on the body chart with a red pen and recorded on a 100 mm Visual Analogue Scale from 0 (no pain) to 100 (unbearable pain).

    Time frame: Within the first 7 days after admission

Secondary outcomes

  1. Awareness Body Chart Questionnaire (ABC)

    Body charts to fill in with colours according to intensity of body awareness. In sum, 51 body regions to colour with 5 different colour pencils (orange = "I can perceive with much detail", yellow = "I can perceive distinctly", green = "I can perceive", blue = "I can perceive indistinctly", black = "I cannot perceive"). To quantify the information, every region of the body will be coded as an extra item and the data of the colours will be transcribed: orange (= 5), yellow (= 4), green (= 3), blue (= 2), black (= 1). Higher values mean higher intensity of body awareness. In the case of pain, the pain location can also be marked on the body chart with a red pen and recorded on a 100 mm Visual Analogue Scale from 0 (no pain) to 100 (unbearable pain).

    Time frame: Before discharge

  2. Like/Dislike Body Chart

    As an extension to the ABC, this questionnaire is intended to answer the question of whether there are areas of the body that one particularly likes about oneself or that one dislikes about oneself. If yes, one can draw these with a purple color pencil ("particularly like") and/or with a gray color pencil ("do not like") in an extra Body Chart.

    Time frame: Within the first 7 days after admission and before discharge

  3. Self-rating mood scale - revised

    Verbal questionnaire concerning mood status. 24 pairs of oppositional adjectives concerning mood: One of them or \<neither nor\> should be ticked, depending on how it best corresponds to the current situation. The negative pole = 2. The positive pole = 0. \<neither nor\> = 1. Higher sum scores indicate worse subjective mood, lower values better mood.

    Time frame: Within the first 7 days after admission and before discharge

  4. Beck Depression Inventory II (BDI-II)

    The BDI-II represents a self-rating instrument to assess the severity of depression. Four statements are given for each of 21 questions, from which the one that best describes how the person has felt in the past week is to be selected. In scoring, each item is given a score of 0 to 3, depending on the choice (higher number means higher depression scores), and after directly adding the scores of the individual items, a total score of 0 to 63 is obtained. A score of 9-13 is considered minimal depression, 14-19 is mild depression, 20-28 is moderate depression, and scores above 29 indicate severe depression.

    Time frame: Within the first 7 days after admission and before discharge

  5. Insomnia Severity Index (ISI)

    The ISI is a self-assessment questionnaire used to evaluate the nature, severity, and impact of insomnia over the past two weeks. The ISI contains seven items rated with a five-point Likert scale (0 = not at all, 4 = very severe problem), with the total score ranging from 0 to 28. Higher scores indicate greater severity of insomnia. Scores from 0-7 are considered no insomnia, 8-14 is subthreshold insomnia, 15-21 is moderate insomnia, and 22-28 is severe insomnia.

    Time frame: Within the first 7 days after admission and before discharge

  6. Simple Physical Activity Questionnaire (SIMPAQ)

    Questionnaire to survey physical activity: It should show a snapshot of hours per day of an average day in the past week. The time in bed, the time while doing sedentary work (including dozing), while walking, while exercising and during other physical activities (such as household chores) is interrogated. The test does not measure the intensity of physical activity, but rather sorts it into the groups walking, sport and other categories.

    Time frame: Within the first 7 days after admission

  7. Short Form 12 Health Survey (SF-12)

    Questionnaire on health-related quality of life. It consists of twelve questions relating to the last four weeks and yields statements about eight different dimensions of subjective health: general health perception, physical health, physically-conditioned role function, physical pain, vitality, mental health, emotionally-related role function, social functionality. Different Likert-Scales are used. A physical sum scale and a psychological sum scale can be calculated. The polarity of four items must be reversed so that higher values in all items and total scales reflect a better state of health. Normative data are available. Values may range from 0-100, with a mean of 50 and a standard deviation of 10 in the general population. Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.

    Time frame: Within the first 7 days after admission

  8. Brief Symptom Inventory (BSI)

    Questionnaire on the burden of symptoms. The BSI is also called the Brief Symptom Check List (BSCL), it is a short form of the SCL-90 (Derogatis, 1993). The BSI consists of 53 items (physical as well as psychological symptoms), which are assessed subjectively on a Likert scale in relation to the last seven days from 0 = "not at all" to 5 = "very strong". The items result in nine scales: somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism.

    Time frame: Within the first 7 days after admission

  9. Demographic data and chronic complaints and current illnesses

    Age, sex, height, weight, body mass index, and further demographic data. Chronic complaints and current illnesses.

    Time frame: Within the first 7 days after admission

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06879977
Lead sponsor
Johannes Kepler University of Linz
Responsible party
Christian Mittermaier (Head of Department, M.D., Johannes Kepler University of Linz) — Principal investigator
First posted
Mar 17, 2025
Start date
Mar 26, 2025
Primary completion
Sep 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 8, 2025

Study contacts

Christian Mittermaier, M.D.
Contact
Christian.Mittermaier@kepleruniklinikum.at
+43 (0)5 7680 83 - 6170

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion